CGTX

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. The Company is investigating its lead candidate, zervimesine (CT1812), in clinical programs in dementia with Lewy bodies (DLB) and Alzheimer’s disease. Its CT1812 and pipeline of sigma-2 modulators can regulate pathways that are impaired in these diseases for the treatment of degenerative diseases. Its lead product candidate, CT1812, is an orally delivered, small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins. Its pipeline candidates were discovered using proprietary biology and chemistry platforms designed to identify novel drug targets and disease-modifying therapies that address dysregulated pathways. It is developing other product candidates in the area of synucleinopathies.

Wall Street analysts forecast CGTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CGTX is 3.00 USD with a low forecast of 3.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Cognition Therapeutics Inc revenue for the last quarter amounts to -6.38M USD, decreased -55.92 % YoY.

Cognition Therapeutics Inc. EPS for the last quarter amounts to USD, decreased -100.00 % YoY.

Cognition Therapeutics Inc (CGTX) has 25 emplpoyees as of December 15 2025.

Today CGTX has the market capitalization of 149.18M USD.